Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927120 · ClinicalTrials.gov registry record · Phase 2
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01927120 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT01927120, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus host disease (GVHD).
Interventions
- DRUG Sirolimus
- DRUG IL-2
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-03-25 |
| Est. Completion | 2017-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927120
The ClinicalTrials.gov registry entry for NCT01927120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sirolimus is the first listed.
NCT01927120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927120 about?
NCT01927120 is a clinical study titled "In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis". IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus host disease (GVHD).
What is the current status of trial NCT01927120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-03-25. Estimated completion is 2017-03-09.
What interventions are being tested in trial NCT01927120?
The interventions under investigation include: Sirolimus (DRUG), IL-2 (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT01927120?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.